Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:06 PM ET 8-K
Loan & Debt Fathom Holdings Inc. FTHM

Fathom Holdings Debt Financing Update with two accredited investors

Fathom Holdings entered into a Third Omnibus Amendment to its Senior Secured Convertible Promissory Notes, extending the maturity date from November 1, 2026, to November 30, 2026. The amendment defers all accrued and unpaid interest until the new maturity date and introduces a weekly extension fee of 0.5% of the outstanding principal amount.

Counterparty
two accredited investors
Term
through Nov 30, 2026
4:06 PM ET 10-Q
Financial Results Slr Hc BDC LLC

Slr Hc BDC Q3 2026 Results: Net Income $761K, Up 24.3% YoY

For the nine months ended September 30, 2026, SLR HC BDC LLC reported total investment income of $7.1 million and net investment income of $3.1 million. The company's net asset value per unit decreased slightly to $20.87 from $21.11 at the end of 2025, while total unitholders' capital grew to $60.7 million due to $16.7 million in capital contributions.

Key figure
Net income $761K · +24.3% YoY
4:06 PM ET 8-K
Financial Results RxSight, Inc. RXST

RxSight Financial Results

RxSight reported Q3 2026 revenue of $24.6 million, a 19% decrease year-over-year, primarily due to competitive pressures. The company highlighted a strengthened commercial leadership team and a $60 million cash infusion from its strategic collaboration with Alcon, ending the quarter with $254.7 million in cash and investments.

Term
3 months

“Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time. We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success.”

Aziz Mottiwala, President and Chief Executive Officer
4:06 PM ET 8-K
Financial Results Sixth Street Specialty Lending, Inc. TSLX

Sixth Street Specialty Lending Financial Results

Sixth Street Specialty Lending reported third quarter 2026 financial results with net investment income of $0.44 per share and a net asset value of $16.19 per share. The company also declared a fourth quarter base dividend of $0.42 per share and a third quarter supplemental dividend of $0.01 per share.

“Our objective is not to compete for the same investments on the same terms, but to bring a differentiated perspective to where and how we invest capital. We believe these capabilities position us well to navigate an increasingly bifurcated market and compound long-term value for our shareholders.”

Bo Stanley, Chief Executive Officer
4:06 PM ET Form 4
Insider Selling Artiva Biotherapeutics, Inc. ARTV

Artiva Biotherapeutics COO, CLO, Compliance Officer Jennifer Bush Sells $35.3K of Stock

Jennifer Bush, COO, CLO, Compliance Officer, sold 8,439 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $35.3K in total on Nov 2, 2026. Shares held after the trade: 357,720 (-2.3%).

Value
$35.3K
Shares
8,439
Price
$4.18
Role
COO, CLO, Compliance Officer
Holding change
-2.3%
Trade date
Nov 2, 2026
4:06 PM ET 8-K
Dividend Pennantpark Investment Corp PNNT

Pennantpark Investment Dividend

PennantPark Investment Corporation declared a monthly distribution for November 2026 of $0.08 per share. The distribution consists of a $0.04 base dividend and a $0.04 supplemental dividend, payable on December 1, 2026, to stockholders of record as of November 13, 2026.

4:06 PM ET 8-K
Shareholder Meeting Regis Corp RGS

Regis Shareholder Meeting

Regis Corporation held its 2026 Annual Meeting where five of six director nominees failed to receive a majority of votes cast, triggering conditional resignation offers under the company's majority voting policy. Shareholders also voted against the advisory 'say-on-pay' proposal regarding executive compensation, while ratifying Grant Thornton LLP as the independent auditor. Separately, the company announced that Jamie Suarez, EVP of Company Operations, will depart the company effective October 30, 2026.

4:06 PM ET 8-K
Leadership Change Erie Indemnity Co ERIE

Erie Indemnity Leadership Change

Timothy G. NeCastro retired as President and CEO effective November 2, 2026, which was an acceleration of his previously announced retirement date. Brian W. Bolash, the company's Executive Vice President, has been appointed Interim President and CEO effective November 3, 2026, while the board continues its search for a permanent successor.

4:06 PM ET 8-K
Dividend Weyco Group Inc WEYS

Weyco Group Dividend

Weyco Group's Board of Directors declared a special cash dividend of $2.00 per share, representing a total cash outlay of approximately $19 million. The dividend is payable on January 8, 2027, to shareholders of record as of November 17, 2026, and is being funded by excess cash on the company's balance sheet.

4:06 PM ET 8-K
M&A Deal Marinemax Inc HZO

Marinemax M&A Deal with Safe Harbor Marinas, LLC

MarineMax announced that all regulatory approvals and clearances have been obtained for its pending merger with affiliates of Safe Harbor Marinas (a Blackstone portfolio company). The company expects the transaction to close by the end of 2026, subject to a shareholder vote scheduled for November 11, 2026.

Counterparty
Safe Harbor Marinas, LLC
4:05 PM ET 8-K12B/A
M&A Deal Real Remax Group Inc. REAX

Real Remax Group M&A Deal with RE/MAX Holdings, Inc.

Real REMAX Group Inc. filed an amendment to its 8-K to provide historical and pro forma financial statements following its completed acquisition of RE/MAX Holdings, Inc. and The Real Brokerage Inc. The transaction, which closed on August 24, 2026, was accounted for as a business combination with Real as the accounting acquiror. The filing also details a $550 million term loan facility and a $40 million revolving credit facility used to finance the combination.

Counterparty
RE/MAX Holdings, Inc.
4:05 PM ET Form 4
Insider Selling Regeneron Pharmaceuticals, Inc. REGN

Regeneron Pharmaceuticals Insider Michael S. Brown Sells $1.69M of Stock

Michael S. Brown sold 1,929 shares of Regeneron Pharmaceuticals, Inc. at $875.00 a share, worth $1.69M in total on Oct 30, 2026. Shares held after the trade: 1,380 (-58.3%).

Value
$1.69M
Shares
1,929
Price
$875.00
Holding change
-58.3%
Trade date
Oct 30, 2026
4:05 PM ET Form 4
Insider Buying Financial Institutions Inc FISI

Financial Institutions Director Andrew W. Dorn Jr. Buys $63.2K of Stock

Andrew W. Dorn Jr., Director, bought 1,575 shares of Financial Institutions Inc at $40.11 a share, worth $63.2K in total on Nov 2, 2026. Shares held after the trade: 40,641 (+4.0%).

Value
$63.2K
Shares
1,575
Price
$40.11
Role
Director
Holding change
+4.0%
Trade date
Nov 2, 2026
4:05 PM ET 8-K
Divestiture Braemar Hotels & Resorts Inc. BHR

Braemar Hotels & Resorts Divestiture to Evergreen Acquisitions, LLC for $372M

Braemar Hotels & Resorts completed the sale of the 210-room Four Seasons Resort Scottsdale to Evergreen Acquisitions, LLC for $372 million in cash. The company expects to use the proceeds to fund remaining fees related to its transition to a self-managed REIT, which is on track for completion in mid-November 2026.

Value
$372M
Counterparty
Evergreen Acquisitions, LLC
4:05 PM ET Form 4
Insider Selling Acuity Inc. (De) AYI

Acuity Inc. (De) President & CEO Neil Ashe Sells $4.23M of Stock

Neil Ashe, President & CEO, sold 13,217 shares of Acuity Inc. (De) at $313.98 to $325.07 a share (average $320.20) in 13 transactions, worth $4.23M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 64,858 (-1.5%).

Value
$4.23M
Shares
13,217
Average price
$320.20
Role
President & CEO
Holding change
-1.5%
Trade date
Oct 30, 2026 to Nov 2, 2026
4:05 PM ET 8-K
Financial Results Skyworks Solutions, Inc. SWKS

Skyworks Solutions Financial Results

Skyworks Solutions reported Q4 fiscal 2026 standalone revenue of $1.046 billion and non-GAAP diluted EPS of $1.28. The company highlighted the completion of its combination with Qorvo, which closed after the quarter end, creating a full-stack RF front-end platform targeting $500 million in annual cost synergies. For the full fiscal year 2026, Skyworks reported revenue of $3.96 billion.

“Combining with Qorvo gives us the scale and the technology breadth to lead the next era of wireless, as AI moves from the infrastructure to the devices, vehicles and machines around us.”

Phil Brace, chief executive officer and president of Skyworks

“Because our combination with Qorvo closed after the end of our fiscal fourth quarter, our reported September-quarter results are Skyworks standalone.”

Philip Carter, chief financial officer and senior vice president of Skyworks
4:05 PM ET 10-Q
Financial Results Arvinas, Inc. ARVN

Arvinas Q3 2026 Results: Net Loss of $53.9M, Loss Widens

Arvinas, Inc. reported total assets of $607.5 million as of September 30, 2026, a decrease from $717.9 million at the end of 2025, primarily driven by a reduction in marketable securities and the recognition of deferred revenue. The company maintains a cash runway expected to fund operations into the second half of 2028, focusing on clinical advancements for candidates like ARV-393 and ARV-027.

Key figure
Net loss $53.9M
4:05 PM ET Form 4
Insider Selling Artiva Biotherapeutics, Inc. ARTV

Artiva Biotherapeutics CEO Fred Aslan Sells $260K of Stock

Fred Aslan, CEO, sold 62,178 shares of Artiva Biotherapeutics, Inc. at $4.18 a share, worth $260K in total on Nov 2, 2026. Shares held after the trade: 1,457,428 (-4.1%).

Value
$260K
Shares
62,178
Price
$4.18
Role
CEO
Holding change
-4.1%
Trade date
Nov 2, 2026
4:05 PM ET 10-Q
Financial Results Vertex Pharmaceuticals Inc VRTX

Vertex Pharmaceuticals Q3 2026 Results: Net Income $654M, Down 39.6% YoY

Vertex Pharmaceuticals reported total revenues of $3.44 billion for the third quarter of 2026, a 12% increase compared to the same period in 2025. Net income for the quarter was $653.6 million, down from $1.08 billion in the prior year, primarily driven by significantly higher operating expenses and a $9.06 billion acquisition of Crinetics Pharmaceuticals.

Key figure
Net income $654M · -39.6% YoY
4:05 PM ET 10-Q
Financial Results Sotera Health Co SHC

Sotera Health Q3 2026 Results: Net Income $58.4M, Up 20.6% YoY

Sotera Health reported a significant increase in net income for the nine months ended September 30, 2026, reaching $138.6 million compared to $43.1 million in the prior year period. This growth was driven by higher service revenues and the absence of the $64.9 million Illinois EO litigation settlement charge that impacted 2025 results.

Key figure
Net income $58.4M · +20.6% YoY
4:05 PM ET 10-Q
Financial Results Transcat Inc TRNS

Transcat Q2 2026 Results: Net Income $2.41M, Up 90.1% YoY

Transcat Inc. reported total revenue of $97.1 million for the second quarter ended September 26, 2026, an 18% increase year-over-year, driven primarily by strong growth in Service revenue. Despite the revenue growth, net income for the six-month period decreased to $3.7 million from $4.5 million in the prior year, impacted by higher operating expenses and interest costs.

Key figure
Net income $2.41M · +90.1% YoY
4:05 PM ET 8-K
Shareholder Meeting Parker-Hannifin Corp PH

Parker-Hannifin Shareholder Meeting

Parker-Hannifin Corporation held its 2026 Annual Meeting of Shareholders on October 28, 2026. Shareholders elected nine directors for terms expiring in 2027, approved executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent accounting firm for fiscal year 2026.

4:05 PM ET 8-K
Financial Results Booking Holdings Inc. BKNG

Booking Holdings Financial Results

Booking Holdings reported Q3 2026 financial results featuring 10% gross bookings growth and a 17% increase in adjusted EPS despite a 1% decline in GAAP revenue. The company recorded a $900 million revenue reduction related to an FTC matter and returned capital to shareholders through $2.1 billion in stock repurchases and a quarterly dividend declaration.

Term
Q3 2026

“We are pleased with our third-quarter operating performance, as resilient travel demand and disciplined execution by our teams drove double-digit gross bookings growth, margin expansion, and 17% adjusted earnings per share growth (GAAP earnings per share growth of 7%)”

Glenn Fogel, Chief Executive Officer of Booking Holdings
4:04 PM ET 10-Q
Financial Results Unitedhealth Group Inc UNH

Unitedhealth Group Q3 2026 Results: Net Income $4.11B, Up 75.0% YoY

For the nine months ended September 30, 2026, UnitedHealth Group reported total revenues of $336.4 billion and net earnings attributable to common shareholders of $15.9 billion, an increase from $12.0 billion in the prior year period. The company maintained a strong balance sheet with $312.8 billion in total assets and returned $11.3 billion to shareholders through dividends and share repurchases during the first nine months of 2026.

Key figure
Net income $4.11B · +75.0% YoY
4:04 PM ET Form 4
Insider Selling Vulcan Materials CO VMC

Vulcan Materials SVP David P. Clement Sells $1.44M of Stock

David P. Clement, SVP, sold 5,000 shares of Vulcan Materials CO at $287.83 to $288.62 a share (average $287.86) in 2 transactions, worth $1.44M in total on Nov 2, 2026. Shares held after the trade: 1,716 (-10.4%).

Value
$1.44M
Shares
5,000
Average price
$287.86
Role
SVP
Holding change
-10.4%
Trade date
Nov 2, 2026
4:04 PM ET 8-K
Financial Results Ardelyx, Inc. ARDX

Ardelyx Financial Results

Ardelyx reported Q3 2026 total product revenue of $125.5 million, a 19% increase year-over-year, driven primarily by $96.3 million in IBSRELA sales. The company reiterated its full-year 2026 revenue guidance for IBSRELA ($350M-$370M) and XPHOZAH ($110M-$120M) while maintaining a strong cash position of $285.3 million.

Term
Q3 2026

“Our third quarter results reflect the strength of the foundation we’ve built. IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”

Mike Raab, President and Chief Executive Officer
4:04 PM ET 8-K
Financial Results Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Financial Results

Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.

“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”

Chris Peetz, Chief Executive Officer of Mirum
4:04 PM ET 8-K
Financial Results Transcat Inc TRNS

Transcat Financial Results

Transcat reported fiscal second quarter 2027 results featuring 18% total revenue growth to $97.1 million and 23% growth in its Service segment. The company achieved its 70th consecutive quarter of Service revenue growth and expanded Service gross margins by 220 basis points to 34%.

Term
Q2 2027

“Our fiscal second quarter results demonstrate strong execution across each pillar of our core strategy: driving strong Service organic revenue growth, expanding Service gross margins, executing strategic acquisitions, and growing Rentals consistently.”

Jaime Irick, President and CEO

“For the full fiscal year 2027, assuming the broader economic environment remains stable, we now expect Service organic revenue growth in the low double digits, up from our prior outlook of high single digits, along with Service gross margin expansion.”

Jaime Irick, President and CEO
4:04 PM ET 8-K
Financial Results Denali Therapeutics Inc. DNLI

Denali Therapeutics Financial Results

Denali Therapeutics reported Q3 2026 financial results, highlighted by $17.8 million in net product revenue for AVLAYAH and a net income of $70.1 million. The company's cash position reached $1.0 billion, bolstered by a $194.0 million net gain from the sale of a Priority Review Voucher.

Term
Q3 2026

“Families and physicians are telling us that AVLAYAH is making a difference for children with Hunter syndrome, and the results this quarter reflect that. The positive responses to AVLAYAH across patients, physicians and payers, and our team’s strong commercial execution, show what is possible for our TransportVehicle portfolio.”

Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.